Skip to main content
Premium Trial:

Request an Annual Quote

Scimagix Integrates Image Management Software with Amersham Platform

NEW YORK, Nov. 6-In a development partnership with Amersham Biosciences, Scimagix will retool its SIMS image management database for use with Amersham's IN Cell Analyzer 3000 screening platform, the company said yesterday.


Amersham's system can be used to monitor cellular processes as they are affected by drug candidates. It is designed to generate up to 30,000 cellular images per day.


Scimagix plans to adapt its database system so that image, annotation and analysis data generated by multiple Amersham platforms in one company can be integrated and organized in an automated fashion. Drug development researchers would be able to access cellular images and data with a web-based browser.


Financial details of this agreement were not reported.


According to Scimagix, one bottleneck in drug development arises because cell-based screening data tends to be isolated and fragmented. Its product is designed to centralize image-based data storage and mining process.


Scimagix is an informatics company based in San Mateo, Calif.


For further information, see the company website.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.